Provided by Tiger Trade Technology Pte. Ltd.

iShares Health Innovation Active ETF

33.80
+0.02710.08%
Post-market: 33.77-0.0271-0.08%16:10 EDT
Volume:222
Turnover:8K
Market Cap:13.52M
PE:- -
High:33.80
Open:33.77
Low:33.80
Close:33.77
52wk High:34.98
52wk Low:27.25
Shares:400.00K
Float Shares:400.00K
Volume Ratio:0.14
T/O Rate:0.06%
Dividend:0.08
Dividend Rate:0.24%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Merck’s Remigromig, a Tri-Specific Agonist of the Wingless-Related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2B/3 Brunello Study of Adults with Diabetic Macular Edema

THOMSON REUTERS
·
Sep 24

Merck & Co Inc: Both Doses of Remigromig were Generally Well Tolerated

THOMSON REUTERS
·
Sep 24

Merck & Co - Both Remigromig Doses Show Non-Inferiority to Ranibizumab at 52 Weeks

THOMSON REUTERS
·
Sep 24

Franchetti Names Banca Akros as New Euronext Growth Advisor

TIPRANKS
·
Sep 24

MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)

GlobeNewswire
·
Sep 24

Hong Kong Market Flash: BOAN BIOTECH Jumps Over 8% in Late Session as BA1203 Gets Clinical Trial Nod from NMPA

Stock News
·
Sep 24

RBC Capital Keeps Their Hold Rating on Merck & Company (MRK)

TIPRANKS
·
Sep 24

Johnson & Johnson (JNJ) Receives a Buy from RBC Capital

TIPRANKS
·
Sep 24

Mesoblast Wins FDA Nod for New Potency Assay on Ryoncil Batches

TIPRANKS
·
Sep 24

Atomo Diagnostics Issues FY26 Results Overview Disclaimer

TIPRANKS
·
Sep 24

US Judge Steps Aside in Dispute over Hawaii Energy Settlement

Reuters
·
Sep 24

Medtronic PLC Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Sep 24

Stoke Therapeutics Names Solid Biosciences CEO Bo Cumbo to Board

Reuters
·
Sep 24

Johnson & Johnson Says New Analysis of Ongoing Phase 3 Trial Data Supports Potential of Multiple Myeloma Combination Therapy

MT Newswires Live
·
Sep 23

J&J Says New Model-Based Analysis Further Supports the Potential of Tecvayli Plus Darzalex Faspro

Reuters
·
Sep 23

Johnson & Johnson: Phase 3 MajesTEC-3 study shows ‘sustained’ disease control

TIPRANKS
·
Sep 23

J&J Says MajesTEC-3 Analysis Projects Near-General-Population Mortality Risk for Tecvayli-Darzalex Combo in Early Relapsed Myeloma

Reuters
·
Sep 23

J&J - Tecvayli Plus Darzalex Faspro Reduces Multiple Myeloma Progression Risk by 90% Versus Standard of Care

THOMSON REUTERS
·
Sep 23

New Model-Based Analysis Further Supports the Potential of Tecvayli® (Teclistamab-Cqyv) Plus Darzalex Faspro® (Daratumumab and Hyaluronidase-Fihj) to Redefine Long-Term Survival Expectations in Early Line Relapsed/Refractory Multiple Myeloma

THOMSON REUTERS
·
Sep 23

J&J - Analysis Estimates 87% of Tecvayli Plus Darzalex Faspro Patients Have Comparable Mortality Risk to General Population

THOMSON REUTERS
·
Sep 23